Hidradenitis suppurativa

28 October, 2023

Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa

2023-10-28T20:24:17+03:00By hiss|Categories: Publications, Therapeutics|Tags: Adalimumab, Hidradenitis suppurativa|

Maria Argyropoulou, Anastasia Trigoni, Jessica Kaffenberger, Dimitra Stergianou, Georgia Damoraki, Elissavet Mingiani, Styliani Micha, Andrew Krispinsky, Parthena Meltzanidou, Theodora Kanni, Elizabeth Lazaridou, Evangelos J. Giamarellos-Bourboulis Dermatology (2023) 239 (5): 746–752 DOI: 10.1159/000531558Download pdf 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. Keywords: Adalimumab, Hidradenitis

1 May, 2021

Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab

2023-02-16T13:26:43+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Dimitra Stergianou, Vassiliki Tzanetakou, Maria Argyropoulou, Theodora Kanni, Pantelis G Bagos, Evangelos J. Giamarellos-Bourboulis Dermatology 2021;237(3):372-377 DOI: 10.1159/000512617 View article 🡇 Keywords: Adalimumab; Carriage; Hidradenitis suppurativa; Response; Staphylococcus aureus

9 June, 2020

MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period

2023-02-16T14:28:16+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Theodora Kanni, Maria Argyropoulou, Charles A Dinarello, John Simard, Evangelos J. Giamarellos-Bourboulis Clinical and Experimental Dermatology 2021 Jan;46(1):162-163 DOI: 10.1111/ced.14333 View article 🡇 Funding XBiotech, Texas Hellenic Sepsis Study Group Keywords: Hidradenitis Suppurativa Related Study: HIDRA04

1 July, 2019

LIGHT

2023-01-09T12:07:43+03:00By hiss|Categories: Completed, Interventional, Studies, Systemic inflammatory disorders|Tags: Hidradenitis suppurativa|

Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description LIGHT is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully

1 May, 2019

Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort

2023-02-16T14:35:12+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Maria Argyropoulou, Theodora Kanni, Miltiades Kyprianou, Nikolaos Melachroinopoulos, Evangelos J. Giamarellos-Bourboulis British Journal of Dermatology 2019 May;180(5):1161-1168 DOI: 10.1111/bjd.17151View article 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. The funder did not have any involvement in the study design, data collection, data analysis, manuscript preparation or

1 August, 2018

Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

2023-02-16T14:38:21+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Theodora Kanni, Othmar Zenker, Maria Habel, Niels C Riedemann, Evangelos J. Giamarellos-Bourboulis British Journal of Dermatology 2018 Aug;179(2):413-419 DOI: 10.1111/bjd.16428View article 🡇 Funding This study was funded in part by InflaRx GmbH, Jena, Germany, and in part by the Hellenic Institute for the Study of Sepsis. Keywords: Hidradenitis Suppurativa; immunology; biomarkers

1 April, 2018

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study

2023-02-16T14:39:19+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Theodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, Aikaterini Pistiki, Michael Stecher, Charles A Dinarello, John Simard, Evangelos J. Giamarellos-Bourboulis Journal of Investigative Dermatology 2018 Apr;138(4):795-801 DOI: 10.1016/j.jid.2017.10.030View article 🡇 Funding This study was supported in part by XBiotech (Austin, TX) and the Hellenic Institute for the Study of Sepsis. Keywords: Hidradenitis Suppurativa Related

1 December, 2016

IFX-1-P2.3

2023-01-09T12:08:40+03:00By hiss|Categories: Completed, Interventional, Studies, Systemic inflammatory disorders|Tags: Hidradenitis suppurativa|

Completed study Official Study Title An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 1 site in Greece Actual enrolment: 12 participants ClinicalTrials.gov Identifier: NCT03001622 EudraCT number: 2016-002988-33 National

1 August, 2016

High Copy Numbers of β-Defensin Cluster on 8p23.1, Confer Genetic Susceptibility, and Modulate the Physical Course of Hidradenitis Suppurativa/Acne Inversa

2023-01-16T01:28:08+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa, PhD|

Evangelos J. Giamarellos-Bourboulis, Matthias Platzer, Ioannis Karagiannidis, Theodora Kanni, Georgios Nikolakis, Jens Ulrich, Michael Bellutti, Harald Gollnick, Michael Bauer, Christos C Zouboulis, Klaus Huse Journal of Investigative Dermatology 2016 Aug;136(8):1592-1598 DOI: 10.1016/j.jid.2016.04.021View article ???? Funding The study was funded in part by the Hellenic Institute for the Study of Sepsis and by

1 January, 2016

Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial

2023-02-16T15:33:15+03:00By hiss|Categories: Publications|Tags: Anakinra, clinical trial, Hidradenitis suppurativa, PhD|

Vassiliki Tzanetakou, Theodora Kanni, Sophia Giatrakou, Alexandros Katoulis, Evangelia Papadavid, Mihai G Netea, Charles A Dinarello, Jos W M van der Meer, Dimitrios Rigopoulos, Evangelos J. Giamarellos-Bourboulis JAMA Dermatology 2016 Jan;152(1):52-59 DOI: 10.1001/jamadermatol.2015.3903View article 🡇 Funding This study was supported in part by the Interleukin Foundation, by grant AI-15614 from the National Institutes